GlassScriptPhysician profile
Nedra Hughes
NPI 1811315948
$6,083.25
in general payments reported to CMS, 2019-2025
27 companies · $2,194 in 2025
The $2,194 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,075 · 2022: $648 · 2023: $898 · 2024: $1,267 · 2025: $2,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,359.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,916.32 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $456.67 | 2021-2025 | |
| Novo Nordisk INC | $361.13 | 2021-2025 | Wegovy |
| Abbott Laboratories | $353.22 | 2023-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.01 | 2021-2023 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $237.09 | 2022-2025 | Austedo Xr |
| Gilead Sciences, INC. | $226.22 | 2022-2025 | Biktarvy |
| Abbvie INC. | $213.76 | 2025 | |
| Vanda Pharmaceuticals INC. | $182.97 | 2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $129.00 | 2025 | Voquezna |
| Ardelyx, INC. | $126.48 | 2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $125.66 | 2025 | Cobenfy |
| Eisai INC. | $125.00 | 2021 | |
| Alkermes, INC. | $125.00 | 2025 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.99 | 2025 | Caplyta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $124.37 | 2025 | Auvelity |
| Lexicon Pharmaceuticals, INC. | $123.51 | 2024 | Inpefa |
| Biohaven Pharmaceuticals, INC. | $121.60 | 2021 | |
| Inspire Medical Systems, INC. | $118.76 | 2023 | Inspire |
| Dexcom, INC. | $115.19 | 2024 | Dexcom G7 Gss (161) |
| Neurelis, INC. | $111.25 | 2023 | Valtoco |
| Horizon Therapeutics Plc | $101.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $97.57 | 2022-2023 | Xarelto |
| Lilly USA, LLC | $91.79 | 2024-2025 | Zepbound, Mounjaro |
| Viiv Healthcare Company | $56.12 | 2024 | Rukobia |
| Atricure, INC. | $25.00 | 2024 | |
| Janssen Biotech, INC. | $22.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nedra Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.